1.Protective effect of autophagy inhibition on ischemia-reperfusion-induced injury of N2a cells.
Zhong-qiang WANG ; Yi YANG ; Tao LU ; Pan LUO ; Jin LI ; Jun-ping WU ; Zhong-zhi TANG ; Qi-ping LU ; Qiu-hong DUAN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2013;33(6):810-816
Autophagy is a conserved and programmed catabolic process that degrades damaged proteins and organelles. But the underlying mechanism and functions of autophagy in the ischemia-reperfusion (IR)-induced injury are unknown. In this study, we employed simulated IR of N2a cells as an in vitro model of IR injury to the neurons and monitored autophagic processes. It was found that the levels of Beclin-1 (a key molecule of autophay complex, Beclin-1/class III PI3K) and LC-3II (an autophagy marker) were remarkably increased with time during the process of ischemia and the process of reperfusion after 90 min of ischemia, while the protein kinases p70S6K and mTOR which are involved in autophagy regulation showed delayed inactivation after reperfusion. Administration of 3-methyladenine (3MA), an inhibitor of class III PI3K, abolished autophagy during reperfusion, while employment of rapamycin, an inhibitor of mTORC1 (normally inducing autophagy), surprisingly weakened the induction of autophagy during reperfusion. Analyses of mitochondria function by relative cell viability demonstrated that autophagy inhibition by 3-MA attenuated the decline of mitochondria function during reperfusion. Our data demonstrated that there were two distinct dynamic patterns of autophagy during IR-induced N2a injury, Beclin-1/class III PI3K complex-dependent and mTORC1-dependent. Inhibition of over-autophagy improved cell survival. These suggest that targeting autophagy therapy will be a novel strategy to control IR-induced neuronal damage.
Adenine
;
analogs & derivatives
;
pharmacology
;
Animals
;
Apoptosis Regulatory Proteins
;
genetics
;
metabolism
;
Autophagy
;
Beclin-1
;
Cell Line, Tumor
;
Cell Survival
;
Mechanistic Target of Rapamycin Complex 1
;
Mice
;
Mitochondria
;
metabolism
;
Multiprotein Complexes
;
antagonists & inhibitors
;
metabolism
;
Neurons
;
drug effects
;
metabolism
;
Neuroprotective Agents
;
pharmacology
;
Phosphatidylinositol 3-Kinases
;
antagonists & inhibitors
;
metabolism
;
Reperfusion Injury
;
metabolism
;
Sirolimus
;
pharmacology
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
;
metabolism
2.Current development of the second generation of mTOR inhibitors as anticancer agents.
Chinese Journal of Cancer 2012;31(1):8-18
The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a "master switch" for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and thus, mTOR has emerged as an important target for the design of anticancer agents. mTOR is found in two distinct multiprotein complexes within cells, mTORC1 and mTORC2. These two complexes consist of unique mTOR-interacting proteins and are regulated by different mechanisms. Enormous advances have been made in the development of drugs known as mTOR inhibitors. Rapamycin, the first defined inhibitor of mTOR, showed effectiveness as an anticancer agent in various preclinical models. Rapamycin analogues (rapalogs) with better pharmacologic properties have been developed. However, the clinical success of rapalogs has been limited to a few types of cancer. The discovery that mTORC2 directly phosphorylates Akt, an important survival kinase, adds new insight into the role of mTORC2 in cancer. This novel finding prompted efforts to develop the second generation of mTOR inhibitors that are able to target both mTORC1 and mTORC2. Here, we review the recent advances in the mTOR field and focus specifically on the current development of the second generation of mTOR inhibitors as anticancer agents.
Antineoplastic Agents
;
pharmacology
;
Cell Proliferation
;
drug effects
;
Furans
;
pharmacology
;
Humans
;
Imidazoles
;
pharmacology
;
Indoles
;
pharmacology
;
Mechanistic Target of Rapamycin Complex 1
;
Mechanistic Target of Rapamycin Complex 2
;
Morpholines
;
pharmacology
;
Multiprotein Complexes
;
antagonists & inhibitors
;
Naphthyridines
;
pharmacology
;
Neoplasms
;
pathology
;
Phosphatidylinositol 3-Kinases
;
antagonists & inhibitors
;
metabolism
;
Proto-Oncogene Proteins c-akt
;
metabolism
;
Purines
;
pharmacology
;
Pyridines
;
pharmacology
;
Pyrimidines
;
pharmacology
;
Quinolines
;
pharmacology
;
Signal Transduction
;
Sirolimus
;
pharmacology
;
TOR Serine-Threonine Kinases
;
antagonists & inhibitors
3.Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways.
Yunfeng FU ; Ya'nan ZHANG ; Fan ZHANG ; Jing LIU ; Rong GUI
Chinese Journal of Hematology 2015;36(9):780-784
OBJECTIVETo explore apoptosis of multiple myeloma (MM) cells and its mechanism by the combined inhibition of mTORC2 signaling pathway and heat shock protein 90.
METHODSThe effects of Rapamycin, 17-AAG and the combination on proliferation of MM cell lines U266 and KM3 were assessed using MTT at different time points (0, 8, 24, 48 hour). Cell apoptosis and cell cycle distribution were measured by flow cytometry. The specific proteins p-AKT (ser473), p-AKT (thr450), p-S6 (S235/236) and AKT were detected by Western blotting.
RESULTSRapamycin, 17- AAG and the combination suppressed the proliferation of MM cell lines U266 and KM3, especially the combination of Rapamycin and 17-AAG synergistically inhibited the proliferation (P<0.05); Rapamycin induced G1 arrest both at 24 and 48 hours, 17-AAG also induced G1 arrest, especially at 48 hours (P<0.01); Rapamycin, 17-AAG alone decreased the expression of AKT and induced MM cell apoptosis to some extent (P<0.01); Chronic rapamycin treatment inhibited mTORC2; Inhibition of both mTORC2 and chaper on pathways degraded AKT and induced MM cell apoptosis, which was significantly higher than that of any single agent (P<0.01).
CONCLUSIONInhibition of both mTORC2 and chaper on pathways decreased the expression of AKT to induce apoptosis of MM cells in vitro.
Apoptosis ; Benzoquinones ; pharmacology ; Cell Cycle ; Cell Division ; Cell Line, Tumor ; drug effects ; HSP90 Heat-Shock Proteins ; metabolism ; Humans ; Lactams, Macrocyclic ; pharmacology ; Mechanistic Target of Rapamycin Complex 2 ; Multiple Myeloma ; pathology ; Multiprotein Complexes ; antagonists & inhibitors ; metabolism ; Proto-Oncogene Proteins c-akt ; metabolism ; Signal Transduction ; Sirolimus ; pharmacology ; TOR Serine-Threonine Kinases ; antagonists & inhibitors ; metabolism
4.beta-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.
Yong Weon YI ; Hyo Jin KANG ; Edward Jeong BAE ; Seunghoon OH ; Yeon Sun SEONG ; Insoo BAE
Experimental & Molecular Medicine 2015;47(2):e143-
An F-box protein, beta-TrCP recognizes substrate proteins and destabilizes them through ubiquitin-dependent proteolysis. It regulates the stability of diverse proteins and functions as either a tumor suppressor or an oncogene. Although the regulation by beta-TrCP has been widely studied, the regulation of beta-TrCP itself is not well understood yet. In this study, we found that the level of beta-TrCP1 is downregulated by various protein kinase inhibitors in triple-negative breast cancer (TNBC) cells. A PI3K/mTOR inhibitor PI-103 reduced the level of beta-TrCP1 in a wide range of TNBC cells in a proteasome-dependent manner. Concomitantly, the levels of c-Myc and cyclin E were also downregulated by PI-103. PI-103 reduced the phosphorylation of beta-TrCP1 prior to its degradation. In addition, knockdown of beta-TrCP1 inhibited the proliferation of TNBC cells. We further identified that pharmacological inhibition of mTORC2 was sufficient to reduce the beta-TrCP1 and c-Myc levels. These results suggest that mTORC2 regulates the stability of beta-TrCP1 in TNBC cells and targeting beta-TrCP1 is a potential approach to treat human TNBC.
Cell Line, Tumor
;
Cell Proliferation
;
Cell Survival/drug effects
;
Cyclin E/genetics/metabolism
;
Dose-Response Relationship, Drug
;
Female
;
Furans/pharmacology
;
Gene Knockdown Techniques
;
Humans
;
Models, Biological
;
Multiprotein Complexes/antagonists & inhibitors
;
Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
;
Phosphorylation/drug effects
;
Protein Kinase Inhibitors/*pharmacology
;
Proteolysis/drug effects
;
Proto-Oncogene Proteins c-myc/genetics/metabolism
;
Pyridines/pharmacology
;
Pyrimidines/pharmacology
;
TOR Serine-Threonine Kinases/*antagonists & inhibitors
;
Triple Negative Breast Neoplasms/genetics/*metabolism
;
beta-Transducin Repeat-Containing Proteins/genetics/*metabolism